A new fibromyalgia medication is giving patients hope in clinical trials. Researchers provided an update on the study at the American College of Rheumatology annual meeting and revealed that their investigation is not over, but the IMC-1 drug is already showing promise. This oral medication is being examined in a randomized, double-blind study that hopes to uncover a link between fibromyalgia and tissue-resident herpes virus.

Click Here to read more